Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Notes Payables (2020 - 2022)

Seres Therapeutics (MCRB) has disclosed Notes Payables for 4 consecutive years, with $456000.0 as the latest value for Q4 2022.

  • Quarterly Notes Payables changed N/A to $456000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $456000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $456000.0 for FY2022, N/A changed from the prior year.
  • Notes Payables hit $456000.0 in Q4 2022 for Seres Therapeutics, down from $9.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $9.3 million in Q3 2021 to a low of $454000.0 in Q4 2020.
  • Historically, Notes Payables has averaged $4.0 million across 3 years, with a median of $3.3 million in 2021.